Advanced search
Publication Cover
Cancer Management and Research Volume 14, 2022 - Issue
Submit an article Journal homepage
73
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors

Daneng Li1 City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5330-7522View further author information
ORCID Icon,
Christina Darden2 RTI Health Solutions, Research Triangle Park, NC, USAView further author information
,
Noran Osman3 TerSera Therapeutics, Deerfield, IL, USAView further author information
,
Salma Sayeed3 TerSera Therapeutics, Deerfield, IL, USAView further author information
,
Laurin Jackson2 RTI Health Solutions, Research Triangle Park, NC, USAView further author information
,
Diana Garbinsky2 RTI Health Solutions, Research Triangle Park, NC, USAView further author information
&
Aman Chauhan4 Markey Cancer Center, University of Kentucky, Lexington, KY, USAView further author information
 show all
Pages 3009-3020 | Received 16 Aug 2022, Accepted 07 Oct 2022, Published online: 27 Nov 2023

References

  • Gustafsson BI, Hauso O, Drozdov I, Kidd M, Modlin M. Carcinoid heart disease. Int J Cardiol. 2008;129(3):318–324. doi:10.1016/j.ijcard.2008.02.019
  • Zuetenhorst JM, Bonfrer JMGM, Korse CM, Bakker R, van Tinteren Taal BG. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-Beta and fibroblast growth factor. Cancer. 2003;97(7):1609–1615. doi:10.1002/cncr.11226
  • Pandit S, Bhusal K. Carcinoid Syndrome. Treasure Island, FL: StatPearls Publishing; 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448096/. Accessed October 10, 2022.
  • Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcome in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. doi:10.1001/jamaoncol.2017.0589
  • Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–534. doi:10.1016/S1470-2045(17)30110-9
  • Anthony L, Ervin C, Lapuerta P, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158–2168. doi:10.1016/j.clinthera.2017.09.013
  • Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res. 2012;5(5):161–168.
  • Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663. doi:10.1200/JCO.2009.22.8510
  • Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:1556–1557. doi:10.1056/NEJMoa1316158
  • Barrows SM, Cai B, Copley-Merriman C, et al. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World J Meta Anal. 2018;6(2):9–20. doi:10.13105/wjma.v6.i2.9
  • Toumpanakis C, Garland J, Marelli L, et al. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther. 2009;30:733–740. doi:10.1111/j.1365-2036.2009.04083.x
  • Ferrari ACR, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics. 2018;73(suppl 1):e490s. doi:10.6061/clinics/2018/e490s
  • Riechelmann RP, Pereira AA, Rego JFM, Costa FP. Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol. 2017;9(2):127–137. doi:10.1177/1758834016675803
  • Burton T, Lapuerta P. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States. Future Oncol. 2018;14(23):2361–2370. doi:10.2217/fon-2018-0129
  • Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–577. doi:10.1097/MPA.0b013e31828e34a4
  • Pavel M, Gross DJ, Benavent M, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Rel Cancer. 2018;25:309–322. doi:10.1530/ERC-17-0455
  • Kulke MH, Hörsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35:14–23. doi:10.1200/JCO.2016.69.2780
  • XERMELO® (telotristat ethyl) [prescribing information]. Deerfield, IL: TerSera Therapeutics; 2020.
  • Strosberg J, Joish VN, Giacalone S, et al. TELEPRO: patient-reported carcinoid syndrome symptom improvement following initiation of telotristat ethyl in the real world. Oncologist. 2019;24:1–7. doi:10.1634/theoncologist.2018-0921
  • Kulke MH, Kennecke HF, Murali K, Joish VN. Changes in carcinoid syndrome symptoms among patients receiving telotristat ethyl in US clinical practice: findings from the TELEPRO-II real-world study. Cancer Manag Res. 2021;13:7439–7446. doi:10.2147/CMAR.S330429
  • Li D, Darden C, Sayeed S, et al. Patient-reported clinical and productivity outcomes from the longitudinal telotristat ethyl treatment registry (98). Presented at: North American Neuroendocrine Tumor Society Annual Meeting; November 4–6; 2021.
  • Darden C, Joish VN, Price MA, et al. Patient-reported activity impairment, work productivity loss, and carcinoid syndrome outcomes: interim analyses of the RELAX patient registry (113). Presented at: North American Neuroendocrine Tumor Society Annual Meeting; October 2–3; 2020.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.